In the Original Investigation titled “Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer,”[1] published May 3, 2021, there were errors in the x-axis tick labels in Figure 4. All of the labels were off by a factor of 10; for example, “6000” should have appeared as “60 000” and so forth along the entire x-axis. This article has been corrected.[1]